What is PTIXW's health score?

Protagenic Therapeutics, Inc.new (PTIXW) has a TradeApes health score of 50 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is PTIXW's estimated fair value?

Based on our 5-year discounted cash flow model, Protagenic Therapeutics, Inc.new's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is PTIXW undervalued or overvalued?

Our model currently rates PTIXW as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for PTIXW... Refresh in a moment for the full analysis.

Protagenic Therapeutics, Inc.new (PTIXW)

Healthcare Fair Value High mixed

Updated: 2026-04-21

TradeApes Score

hold

Financial Strength

50 Mixed

Operating Trend

60 Healthy

Relative Value

40 Weak

Capital Allocation

50 Mixed

Risk

50 Mixed

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Altman Z-Score in distress zone — elevated bankruptcy risk

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.